Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)

07/30/2021 | 07:41am EDT

Item 8.01. Other Events.


On June 26, 2021, BeiGene, Ltd. (the "Company" or "BeiGene") announced that
BRUKINSA® (zanubrutinib) has been approved by Health Canada for the treatment of
mantle cell lymphoma (MCL) in adult patients who have received at least one
prior therapy. This is the second approval for BRUKINSA in Canada, following its
initial approval in March 2021 for adult patients with Waldenström's
macroglobulinemia (WM). The full text of this press release is filed as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

On June 29, 2021, the Company announced positive topline results from an interim
analysis of the Phase 3 SEQUOIA trial comparing BRUKINSA® (zanubrutinib) to
bendamustine and rituximab (B+R) in patients with treatment-naïve (TN) chronic
lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose tumor did
not exhibit the deletion of chromosome 17p13.1 (del[17p]). The full text of this
press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is
incorporated herein by reference.


Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

   Exhibit No.            Description

       99.1               Press Release titled "BeiGene Announces Approval in Canada of BRUKINSA®
                          (Zanubrutinib) for the Treatment of Patients with Mantle Cell Lymphoma",
                          issued by BeiGene, Ltd. on June 26, 2021.

       99.2               Press Release titled "BeiGene Announces Positive

Topline Results from Phase 3

                          SEQUOIA Trial Comparing BRUKINSA® (Zanubrutinib) 

to Bendamustine Plus

                          Rituximab in Patients with Treatment-Naïve 

Chronic Lymphocytic Leukemia",

                          issued by BeiGene, Ltd. on June 29, 2021.

       104                The cover page from this Current Report on Form

8-K, formatted in Inline XBRL

--------------------------------------------------------------------------------
                                 Exhibit Index

   Exhibit No.            Description

       99.1                 Press Release titled "    BeiGene Announces Approval in Canada of
                          BRUKINSA    ®     (Zanubrutinib) for the

Treatment of Patients with Mantle

                          Cell Lymphoma    ", issued by BeiGene, Ltd. on 

June 2 6 , 2021.


       99.2                 Press Release titled "    BeiGene Announces 

Positive Topline Results from

                          Phase 3 SEQUOIA Trial Comparing     BRUKINSA    

® (Zanubrutinib) to

                          Bendamustine Plus Rituximab in Patients with 

Treatment-Naïve Chronic

                            Lymphocytic Leukemia    ", issued by BeiGene, 

Ltd. on June 29, 2021.

       104                The cover page from this Current Report on Form

8-K, formatted in Inline XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about BEIGENE, LTD.
09/17Asian ADRs Move Lower in Friday Trading
MT
09/17US Futures Modestly Lower Ahead of Fed Meeting Next Week
MT
09/17BEIGENE : Receives Positive Opinion for Brukinsa by European Medicines Agency; S..
MT
09/17Top Premarket Gainers
MT
09/17BEIGENE : Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Tr..
BU
09/17BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the T..
CI
09/17BeiGene Gets CHMP Backing of Brukinsa in Waldenstrom's Macroglobulinemia
DJ
09/16Health Care Stocks Largely Sitting Out Markets Recovery This Afternoon
MT
09/16Health Care Stocks Falling Thursday Afternoon
MT
09/16INSIDER SELL : Beigene
MT
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations